Chimagen Biomedical

Chimagen Biosciences is a clinical-stage biotechnology company based in China, specializing in the discovery and development of novel multi-specific T cell-engagers and NK cell-engagers. The company utilizes its proprietary antibody engineering platforms to create breakthrough therapies for cancer and autoimmune diseases. In October 2024, Chimagen reached a significant agreement with GSK, which acquired the global rights to CMG1A46, a dual CD19 and CD20-targeted T cell-engager, for $300 million upfront. Chimagen continues to advance its internal pipeline, which includes trispecific antibodies targeting solid tumors and hematologic malignancies. The company's mission is to deliver innovative medicine to address unmet medical needs in oncology and immunology, operating out of facilities in Shanghai and Chengdu.